Predicting response to immune checkpoint inhibitor plus chemotherapy in EGFR-mutant lung adenocarcinoma following first-generation TKI resistance: a multicenter deep learning study - Quiz - MDSpire

Assessing Treatment Response to Immune Checkpoint Inhibitors Combined with Chemotherapy in EGFR-Mutant Lung Adenocarcinoma After Resistance to First-Generation TKIs: Insights from a Multicenter Deep Learning Analysis

  • By

  • Shuai Qie

  • Yasong Shi

  • Jingyun Li

  • Sicong Jia

  • Xiaoping Yin

  • July 17, 2026

Share

Original Source(s)

Predicting response to immune checkpoint inhibitor plus chemotherapy in EGFR-mutant lung adenocarcinoma following first-generation TKI resistance: a multicenter deep learning study

  • by Shuai Qie, Yasong Shi, Jingyun Li, Sicong Jia, Xiaoping Yin

  • July 17, 2026

Related Content

Case Report: immune checkpoint inhibitor-associated aseptic meningitis in lung cancer: two cases illustrating an exclusion-based diagnosis approach and stepwise immunosuppressive treatment

Transcriptomic differences in chromatin and cell cycle regulation in A549 cells after irradiation with carbon ions and X-rays

Research progress of small molecule targeted drugs for non-small cell lung cancer